Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Incyte

Regeneron’s COVID-19 antibody cocktail scores FDA emergency approval

Regeneron’s COVID-19 antibody cocktail scores FDA emergency approval

Last week, Eli Lilly and Incyte’s repurposed arthritis treatment baricitinib also scored an EUA in combination with Gilead’s remdesivir for the treatment of hospitalised COVID-19 patients.

Lilly’s repurposed COVID-19 med baricitinib bags FDA emergency approval

Lilly’s repurposed COVID-19 med baricitinib bags FDA emergency approval Drug approved for emergency use in combination with Gilead's remdesivir. Eli Lilly and Incyte’s arthritis treatment baricitinib has been repurposed as a COVID-19 treatment, scoring an emergency use

Switzerland: a life sciences hub

Switzerland: a life sciences hub American oncology specialist Incyte invested $100m for a monoclonal antibody production site in Yverdon (Vaud).

Incyte launches award programme recognising innovation in GVHD community

Incyte launches award programme recognising innovation in GVHD community have a devastating impact on the lives of patients,” said Barry Flannelly, executive vice president and general manager, US, Incyte. ... Through the Incyte Ingenuity Award, we hope to spark creativity and innovation, which we expect to result in

Incyte’s JAK inhibitor cream clears second eczema trial

Incyte’s JAK inhibitor cream clears second eczema trial Set for regulatory filings later this year. Incyte now has a pair of positive phase 3 trials for its topical formulation of JAK1/2 inhibitor ruxolitinib in atopic dermatitis or eczema, ... Incyte has said it intends to market ruxolitinib cream itself in

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 700 experts delivering world-class...

Latest intelligence

digital launch
How can virtual pharma companies de-risk new product launches?
The risks and challenges involved in taking specialty drugs, biopharmaceuticals and drug/device combinations to market...
Not waving but drowning. Reflections on data curation in the age of information overload
...
digital healthcare chronic disease
Digital healthcare may revolutionise management of chronic diseases, but who is going to pay for it?
Providers are looking at digital solutions to transform this area of healthcare...

Infographics